AstraZeneca Tagrisso plus chemotherapy approved in EU for EGFR-mutated advanced lung cancer Ruchika Sharma8 July 2024 11:30 AM ISTCambridge: AstraZeneca has announced that Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy has been...
AstraZeneca Tagrisso gets USFDA priority review for unresectable, Stage III EGFR-mutated lung cancer Ruchika Sharma11 Jun 2024 11:39 AM ISTAstraZeneca's supplemental New Drug Application (sNDA) for TAGRISSO (osimertinib) has been accepted and granted Priority Review in the US for the...
AstraZeneca Tagrisso, chemotherapy recommended for approval in EU by CHMP for EGFR-mutated advanced lung cancer Ruchika Sharma5 Jun 2024 2:00 PM ISTCambridge: AstraZeneca's Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy has been recommended for...
CDSCO Panel Approves AstraZeneca's Protocol Amendment Proposal For Anti-cancer Drug Osimertinib Dr. Divya Colin25 March 2024 5:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
AstraZeneca Tagrisso with chemotherapy approved in US for EGFR-mutated advanced lung cancer Ruchika Sharma17 Feb 2024 12:00 PM ISTTagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including against CNS metastases.
Treatment with EGFR inhibitors in lung cancer patients tied to increased risk of new-onset keratitis: JAMA Medha Baranwal16 Jan 2024 3:00 AM ISTUSA: A US population-based cohort study showed an increased risk of new-onset keratitis in patients with lung cancer treated with epidermal growth...
Janssen seeks USFDA nod for Rybrevant plus chemotherapy for patients with EGFR-Mutated Non-Small Cell Lung Cancer who progressed on or after Osimertinib Ruchika Sharma23 Nov 2023 2:30 PM ISTRaritan: The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the submission of a supplemental Biologics License ...
AstraZeneca gets USFDA priority review for Tagrisso plus chemotherapy for EGFR-mutated advanced lung cancer Ruchika Sharma17 Oct 2023 2:24 PM ISTCambridge: AstraZeneca’s supplemental New Drug Application (sNDA) for Tagrisso (osimertinib) in combination with chemotherapy has been accepted and...
Phase 3 Mariposa study evaluating Rybrevant plus Lazertinib meets primary endpoint in PFS in Non-Small Cell Lung Cancer: Janssen Ruchika Sharma2 Oct 2023 10:00 AM ISTRartan: The Janssen Pharmaceutical Companies of Johnson & Johnson has announced positive topline results from the Phase 3 MARIPOSA study...
AstraZeneca declares positive results from trial of Tagrisso plus chemotherapy to treat EGFR-mutated advanced lung cancer Ruchika Sharma12 Sept 2023 1:30 PM ISTCambridge: AstraZeneca has announced positive results from FLAURA2 phase III trial of Tagrisso (osimertinib) in combination with chemotherapy for...
Janssen declares positive topline results from Phase 3 study evaluating RYBREVANT given with, without lazertinib combined with chemotherapy versus chemotherapy alone Ruchika Sharma9 Sept 2023 1:45 PM ISTNew Jersey: The Janssen Pharmaceutical Companies of Johnson & Johnson has announced positive topline results from the three-arm Phase 3 ...
Lung cancer pill drastically cuts risk of death after surgery Roshni Dhar7 Jun 2023 5:43 PM ISTA once-daily pill halved people’s risk of dying from a common lung cancer when they took the drug after tumour-removal surgery, trial results from a...
